External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme (Q36017256)

11 August 2017

External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme (English)

1 reference

11 August 2017

Ian Ellis

5

0 references

author name string

John M S Bartlett

1

1 reference

11 August 2017

Merdol Ibrahim

2

1 reference

11 August 2017

Bharat Jasani

3

1 reference

11 August 2017

John M Morgan

4

1 reference

11 August 2017

Elaine Kay

6

1 reference

11 August 2017

Hilary Magee

7

1 reference

11 August 2017

Sarah Barnett

8

1 reference

11 August 2017

Keith Miller

9

1 reference

11 August 2017

language of work or name

English

0 references

publication date

8 September 2006

1 reference

Journal of Clinical Pathology

11 August 2017

1 reference

11 August 2017

60

1 reference

11 August 2017

7

1 reference

11 August 2017

816-819

1 reference

Best Practice No 176: Updated recommendations for HER2 testing in the UK

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

The clinical evaluation of HER-2 status: which test to use?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Variation in rates of oestrogen receptor positivity in breast cancer again

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

The role of HER-2 expression in predicting response to therapy in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

Evaluating HER2 amplification and overexpression in breast cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1995794

23 September 2018

Identifiers

DOI

10.1136/JCP.2006.040840

1 reference

11 August 2017

1 reference

11 August 2017

1 reference